Desvenlafaxine Succinate Tablet, Film Coated, Extended Release
Product Images NDC 71335-1150

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine Succinate (NDC 71335-1150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

E33fdabd C42d 47bf Af0a 1b6d3637f519 01

Chemical structure of 50 mg Desvenlafaxine Succinate, showing the molecular arrangement including aromatic rings and succinate moiety typical of the extended-release oral tablet form.*

FDA Label Image

E33fdabd C42d 47bf Af0a 1b6d3637f519 02

A figure titled 'Impact of Intrinsic Factors (Renal, Hepatic Impairment and Population Description) on Desvenlafaxine Pharmacokinetics' presenting geometric mean ratios with 90% confidence intervals for Cmax and AUC. The chart compares renal impairment (mild to ESRD), hepatic impairment (mild to severe), and population factors (gender and age groups) relative to a reference, showing changes in pharmacokinetic parameters for Desvenlafaxine.*

FDA Label Image

E33fdabd C42d 47bf Af0a 1b6d3637f519 03

A scientific figure titled 'Effect of Other Drugs on Desvenlafaxine Pharmacokinetics' showing the geometric mean ratio (90% CI) of changes in Cmax and AUC caused by the CYP3A4 inhibitor Ketoconazole. The graph displays data points with confidence intervals indicating an increase in both Cmax and AUC relative to reference values.*

FDA Label Image

E33fdabd C42d 47bf Af0a 1b6d3637f519 04

A forest plot graph titled 'Effects of Desvenlafaxine on Pharmacokinetics of Other Drugs' showing geometric mean ratios with 90% confidence intervals for several interacting drugs across different Desvenlafaxine doses. The graph includes data for drugs Desipramine, Midazolam, Tamoxifen, and Aripiprazole, with points plotted for Cmax and AUC pharmacokinetic parameters relative to reference values.*

FDA Label Image

E33fdabd C42d 47bf Af0a 1b6d3637f519 05

A line graph titled 'Estimated Proportion of Relapses vs. Number of Days since Randomization (Study 5)' showing the estimated proportion of patients with relapse (%) over time (days from randomization) up to 200 days. The graph compares two groups: Desvenlafaxine extended-release tablets 50 mg (solid line) and Placebo (dashed line), with the placebo group showing a higher relapse rate over time.*

FDA Label Image

E33fdabd C42d 47bf Af0a 1b6d3637f519 06

A line graph comparing the estimated proportion of patients with relapse (%) over time (days from randomization) for Desvenlafaxine extended-release tablets and placebo. The x-axis represents time to relapse in days (up to 180), and the y-axis shows the proportion of patients with relapse up to 50%. The graph shows two distinct curves, one solid line for Desvenlafaxine and one dashed line for placebo.*

FDA Label Image

Label Image (Lbl713351150)

Label for Desvenlafaxine ER 50 mg tablet, film-coated, extended release, packaged by Bryant Ranch Prepack in Burbank, CA. The label compares the product to Pristiq 50 mg tablet by Lupin Limited. It specifies storage at 20°-25°C (68°-77°F) and includes a safety warning to keep drugs out of reach of children. The package contains 30 tablets and displays the NDC 71335-1150-1 with a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.